# EDGAR Filing Document

**Accession Number:** 0001819794
**File Stem:** 0001641172-25-022763
**Filing Date:** 2025-8
**Character Count:** 121842
**Document Hash:** 8174d5c99d4f6ff99873b09ee9717482
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001641172-25-022763.hdr.sgml**: 20250808

**ACCESSION NUMBER**: 0001641172-25-022763

**CONFORMED SUBMISSION TYPE**: F-3

**PUBLIC DOCUMENT COUNT**: 20

**FILED AS OF DATE**: 20250808

**DATE AS OF CHANGE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Fusion Fuel Green PLC
- **CENTRAL INDEX KEY:** 0001819794
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTRICAL INDUSTRIAL APPARATUS [3620]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L2
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** F-3
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-289429
- **FILM NUMBER:** 251198643

**BUSINESS ADDRESS:**
- **STREET 1:** 10 EARLSFORT TERRACE
- **STREET 2:** DUBLIN 2
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** D02 T380
- **BUSINESS PHONE:** 351 21 581 8802

**MAIL ADDRESS:**
- **STREET 1:** 10 EARLSFORT TERRACE
- **STREET 2:** DUBLIN 2
- **CITY:** DUBLIN
- **STATE:** L2
- **ZIP:** D02 T380

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Fusion Fuel Green Ltd
- **DATE OF NAME CHANGE:** 20200731

**As filed with the Securities and Exchange Commission on August 8, 2025**

**Registration No. 333-**

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, DC 20549**

**FORM F-3**

**REGISTRATION STATEMENT UNDER** 

**THE SECURITIES ACT OF 1933**

**FUSION FUEL GREEN PLC**

(Exact name of registrant as specified in its charter)

**Not Applicable**

(Translation of registrant's name into English)

---

| | |
|:---|:---|
| **Ireland** | **Not Applicable** |
| (State or Other Jurisdiction of<br> Incorporation or Organization) | (I.R.S. Employer<br> Identification Number) |

---

**9 Pembroke Street Upper**

**Dublin D02 KR83**

**Ireland**

**+353 1 961 9350**

(Address and telephone number of registrant's principal executive offices)

---

| |
|:---|
| **CT Corporation System**<br> **28 Liberty Street**<br> **New York, NY 10005**<br> **(212) 894-8940** <br> (Name, address, and telephone number of agent for service) |
| <br> ***Copies to:*** |
| **Louis A. Bevilacqua, Esq.**<br> **Bevilacqua PLLC**<br> **1050 Connecticut Avenue, NW, Suite 500**<br> **Washington, DC 20036**<br> **202-869-0888** |

---

**Approximate date of commencement of proposed sale to the public:** From time to time after this Registration Statement becomes effective.

If only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box. ☐

If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. ☒

If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ☐

If this Form is a registration statement pursuant to General Instruction I.C. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box. ☐

If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.C. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box. ☐

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933.

Emerging growth company ☒

If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

† The term "new or revised financial accounting standard" refers to any update issued by the Financial Accounting Standards Board to its Accounting Standards Codification after April 5, 2012.

**The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended, or until this registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to said Section 8(a), may determine.**

**The information in this preliminary prospectus is not complete and may be changed. These securities may not be sold until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and it is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.**

**SUBJECT TO COMPLETION**

**PRELIMINARY PROSPECTUS DATED AUGUST 8, 2025**

**Up to 3,244,660 Class A Ordinary Shares**

**Fusion Fuel Green PLC**

This prospectus relates to the offer and resale from time to time by the selling shareholders identified in "*Selling Shareholders*" on page 11 (the "Selling Shareholders") of up to 3,244,660 Class A ordinary shares with a nominal value of $0.0035 each ("Class A Ordinary Shares") of Fusion Fuel Green PLC, an Irish public limited company (the "Company," "Fusion Fuel," "we," "us" or "our"). The Class A Ordinary Shares offered hereby consist of:

● 269,459 Class A Ordinary Shares currently outstanding and issued on July 25, 2025 (the "SPA Shares") to the Selling Shareholders pursuant to that certain Securities Purchase Agreement, dated as of July 22, 2025, by and between the Company and the Selling Shareholders (the "July 2025 Securities Purchase Agreement");

● 541,706 Class A Ordinary Shares (the "Pre-Funded Warrant Shares") issuable upon the exercise of pre-funded warrants (the "Pre-Funded Warrants") issued to the Selling Shareholders on July 25, 2025 pursuant to the July 2025 Securities Purchase Agreement, which are exercisable for Class A Ordinary Shares at an exercise price per share of $0.0035 per share, without giving effect to applicable limitations or restrictions on exercise;

● 1,622,330 Class A Ordinary Shares (the "Market Price Warrant Shares") issuable upon the exercise of warrants (the "Market Price Warrants") issued to the Selling Shareholders on July 25, 2025 pursuant to the July 2025 Securities Purchase Agreement, which are exercisable at an exercise price per share of $4.926 per share, without giving effect to applicable limitations or restrictions on exercise; and

● 811,165 Class A Ordinary Shares (the "200% Price Warrant Shares" and together with the Pre-Funded Warrant Shares and the Market Price Warrant Shares, the "Warrant Shares") issuable upon the exercise of warrants (the "200% Price Warrants") issued to the Selling Shareholders on July 25, 2025 pursuant to the July 2025 Securities Purchase Agreement, which are exercisable at an exercise price per share of $9.852, without giving effect to applicable limitations or restrictions on exercise.

Collectively, the SPA Shares, the Pre-Funded Warrants, the Market Price Warrants, and the 200% Price Warrants are referred to herein as the "July 2025 Securities", the Pre-Funded Warrants, the Market Price Warrants, and the 200% Price Warrants are referred to together as the "July 2025 Warrants", and, the SPA Shares, the Pre-Funded Warrant Shares, the Market Price Warrant Shares, and the 200% Price Warrant Shares, are referred to herein as the "Registrable Securities".

Each of the July 2025 Warrants may not be exercised to the extent that, after giving effect to such exercise, its holder (together with any of its affiliates) would beneficially own in excess of 4.99% (the "2025 Warrants Beneficial Ownership Limitation") of Class A Ordinary Shares outstanding immediately after giving effect to such exercise. The 2025 Warrants Beneficial Ownership Limitation may be raised or lowered to any other percentage not in excess of 9.99%, at the option of each holder, provided that any increase will only be effective upon 61 days' prior written notice to the Company. The number of Class A Ordinary Shares being offered for resale under this prospectus does not take into account any limitations on the exercise of the July 2025 Warrants.

We are registering the Registrable Securities pursuant to the July 2025 Securities Purchase Agreement and the resale registration undertaking contained therein. Accordingly, we are not selling any securities under this prospectus and will not receive any proceeds from the sale of any Registrable Securities. Notwithstanding the foregoing, we may receive proceeds upon any cash exercise of the July 2025 Warrants. If all such warrants were exercised for cash at their respective exercise prices on the date of this prospectus, we would receive aggregate gross proceeds of approximately $15,985,091. We intend to use such proceeds, if and when received, for working capital and general corporate purposes. The July 2025 Warrants also provide for exercise on a cashless basis if there is no effective registration statement registering, or the prospectus is not available for, the resale of Class A Ordinary Shares underlying the respective July 2025 Warrants. To the extent that the July 2025 Warrants are exercised on a cashless basis, we would not receive any proceeds from such exercise. See "*Use of Proceeds*".

Except to the extent limited by the 2025 Warrants Beneficial Ownership Limitation, from and after the effective date of the registration statement of which this prospectus forms a part, the Selling Shareholders may sell or otherwise dispose of the Registrable Securities from time to time and at any time while the registration statement of which this prospectus forms a part is effective, in one or more transactions, at market prices prevailing at the time of sale, at prices related to such prevailing market prices, at fixed prices or in negotiated transactions. We will pay the expenses of registering the Registrable Securities, while the Selling Shareholders will pay any selling or other expenses incurred as a result of their sale of any such Registrable Securities. See "*Plan of Distribution*".

The Class A Ordinary Shares and the Company's public warrants are both listed on The Nasdaq Capital Market tier of The Nasdaq Stock Market LLC ("Nasdaq") under the symbol "HTOO" and "HTOOW", respectively. The last reported sale price of the Class A Ordinary Shares and the Company's public warrants on The Nasdaq Capital Market on August 7, 2025 was $4.52 and $0.0351, respectively.

**Investing in our securities is highly speculative and involves a high degree of risk. See "*Risk Factors*" beginning on page 4 of this prospectus, in any applicable prospectus supplement, and as described in certain of the documents we may incorporate by reference herein, for a discussion of information that should be considered in connection with an investment in our securities.**

**Neither the Securities and Exchange Commission nor any state or provincial securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.**

**The date of this prospectus is , 2025.**

**<u>**TABLE OF CONTENTS**</u>**

---

| | |
|:---|:---|
|  | **Page** |
| [About This Prospectus](#a_001) | 1 |
| [Prospectus Summary](#a_002) | 2 |
| [Risk Factors](#a_003) | 4 |
| [Cautionary Note Regarding Forward-Looking Statements](#a_004) | 5 |
| [Use of Proceeds](#a_005) | 6 |
| [Dividend Policy](#a_006) | 7 |
| [July 2025 Private Placement](#a_007) | 8 |
| [Description of Securities](#a_008) | 10 |
| [Selling Shareholders](#a_009) | 11 |
| [Plan of Distribution](#a_010) | 13 |
| [Expenses Related to the Offering](#a_011) | 15 |
| [Legal Matters](#a_012) | 16 |
| [Experts](#a_013) | 17 |
| [Indemnification](#a_014) | 18 |
| [Enforcement of Civil Liabilities](#a_015) | 19 |
| [Material Changes](#a_016) | 20 |
| [Where You Can Find More Information; Documents Incorporated by Reference](#a_017) | 21 |

---

i

**ABOUT THIS PROSPECTUS**

This prospectus is part of a registration statement on Form F-3 filed with the U.S. Securities and Exchange Commission (the "SEC") to register the Registrable Securities for resale by the Selling Shareholders who may, from time to time and subject to applicable limitations, if any, sell such securities. See "*Plan of Distribution*" for more information.

We may, from time to time, file one or more prospectus supplements, or, when appropriate, post-effective amendments, to update, add to, or otherwise modify the information in this prospectus. If a prospectus supplement or post-effective amendment conflicts with any statement in this prospectus, the newer document will control. We may also authorize one or more free writing prospectuses that provide additional material information about this offering. Accordingly, you should read this prospectus together with any prospectus supplement, any post-effective amendment, and any related free writing prospectus, and all information that we incorporate by reference or attach to those documents. See "*Where You Can Find More Information; Documents Incorporated by Reference*" for more information. You are also strongly urged to review carefully the matters discussed under "*Risk Factors*" in this prospectus, in each prospectus supplement, in any post-effective amendment, in any related free writing prospectus, and in any other documents that we incorporate by reference.

Neither we, nor the Selling Shareholders, have authorized anyone to provide you with any information or to make any representations other than those contained in this prospectus, any post-effective amendment, or any applicable prospectus supplement or free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the Selling Shareholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. The Selling Shareholders will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus, any post-effective amendment and any applicable prospectus supplement or free writing prospectus is accurate only as of the date on its respective cover and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference or, in each case, any earlier date specified for such information, unless we indicate otherwise. Our business, financial condition, results of operations and prospects may have changed since those dates. To the extent there is a conflict between the information contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference filed with the SEC before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document incorporated by reference is inconsistent with a statement in another document incorporated by reference having a later date, the statement in the document having the later date modifies or supersedes the earlier statement.

This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See "*Risk Factors*" and "*Cautionary Note Regarding Forward-Looking Statements*" appearing in this prospectus and in the documents we file with the SEC that are incorporated by reference into this prospectus.

For investors outside of the United States: Neither we nor the Selling Shareholders have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside the United States.

We use various trademarks, trade names and service marks in our business. For convenience, we may not include the "℠", "<sup>®</sup>" or "<sup>™</sup>" status symbols for these marks, but such omission is not meant to indicate that we would not protect our intellectual property rights to the fullest extent allowed by law. Any other trademarks, trade names or service marks referred to in this prospectus are the property of their respective owners.

We are responsible for the information contained in or incorporated by reference into this prospectus. This prospectus includes or incorporates by reference industry and market data that we obtained from periodic industry publications, third-party studies and surveys, filings of public companies in our industry or internal company surveys. These sources generally state that the information they provide has been obtained from sources believed to be reliable, but that the accuracy and completeness of the information are not guaranteed. The forecasts and projections are based on historical market data, and there is no assurance that any of the forecasts or projected amounts will be achieved. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with complete certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data gathering process and other limitations and uncertainties. The market and industry data used in or incorporated by reference into this prospectus involve risks and uncertainties that are subject to change based on various factors, including those discussed in or incorporated by reference into the section titled "*Risk Factors*", any applicable prospectus supplement, and the documents incorporated by reference herein. These and other factors could cause results to differ materially from those expressed in, or implied by, the estimates made by independent parties and by us. Furthermore, we cannot assure you that a third party using different methods to assemble, analyze or compute industry and market data would obtain the same results.

PROSPECTUS SUMMARY

 

*This summary highlights selected information contained elsewhere in or incorporated by reference into this prospectus. This summary is not complete and does not contain all of the information that you should consider before deciding whether to invest in the Class A Ordinary Shares. This summary is qualified in its entirety by the more detailed information included in or incorporated by reference into this prospectus and any applicable prospectus supplement and the other documents incorporated by reference into this prospectus. You should carefully read the entire prospectus and the other documents incorporated by reference into this prospectus, including the risks associated with an investment in our company discussed in the "*Risk Factors*" section of this prospectus, any applicable prospectus supplement, and documents referred to in "*Where You Can Find More Information; Documents Incorporated by Reference*," before making an investment decision. Some of the statements in this prospectus and the other documents incorporated by reference into this prospectus are forward-looking statements. See the section titled "*Cautionary Note Regarding Forward-Looking Statements*".*

**Overview**

Fusion Fuel is a leading provider of full-service energy engineering and advisory solutions, specializing in green hydrogen and industrial gas applications. Through its two operating subsidiaries, Bright Hydrogen Solutions Ltd and Al Shola Al Modea Gas Distribution LLC, Fusion Fuel offers a broad portfolio of services, including the design, supply, installation, and maintenance of energy systems, as well as the transport and distribution of liquefied petroleum gas. The Company serves a diverse customer base spanning commercial buildings, mixed-use developments, heavy industries, and food service sectors, while continuing to drive innovation in the renewable energy space. Fusion Fuel is committed to advancing the global energy transition by delivering sustainable, efficient, and reliable energy solutions.

For additional information about the Company, see Item 4. "Information on the Company" in the Company's Annual Report on [Form 20-F](https://www.sec.gov/Archives/edgar/data/1819794/000121390025041617/ea0240743-20f_fusion.htm) for the fiscal year ended December 31, 2024 filed with the SEC on May 9, 2025, which is incorporated by reference herein.

The Company's Class A Ordinary Shares are traded on The Nasdaq Capital Market under the ticker symbol "HTOO" and its warrants are traded under the ticker symbol "HTOOW."

**July 2025 Private Placement**

 ****

Under the July 2025 Securities Purchase Agreement, the Company issued and sold, and the Selling Shareholders acquired, the July 2025 Securities, consisting of (i) the 269,459 SPA Shares, and (ii) the July 2025 Warrants to purchase up to 2,975,201 Class A Ordinary Shares (subject to adjustments from time to time, if any) for an aggregate purchase price of $4,300,000 (such transaction, the "July 2025 Private Placement"). The July 2025 Securities Purchase Agreement requires the Company to use the net proceeds from the sale of the Class A Ordinary Shares and the July 2025 Warrants to repay in full any indebtedness owed pursuant to each Senior Convertible Note, dated as of January 10, 2025, issued by the Company, and each Senior Convertible Note, dated as of March 3, 2025, issued by the Company (collectively, the "2025 Notes"), with any balance remaining to be used for general corporate and working capital purposes and to pay any fees and expenses in connection with the transactions contemplated by such offering. See "*July 2025 Private Placement*" for more information.

**July 2025 Reverse Share Split** 

On July 11, 2025, we implemented a one-for-thirty-five (1:35) share consolidation of our Class A Ordinary Shares (the "July 2025 Reverse Share Split"), under which every thirty-five (35) issued and outstanding or authorized and unissued Class A Ordinary Shares with a nominal value of $0.0001 were automatically combined and converted into one (1) Class A Ordinary Share with a nominal value of $0.0035. Immediately following the implementation of the July 2025 Reverse Share Split, the Company implemented an increase of its authorized share capital such that the Company remained authorized to issue 100,000,000 Class A Ordinary Shares. No fractional shares were issued in connection with the July 2025 Reverse Share Split; instead, any fractional shares resulting from the split were rounded up to the nearest whole share. The purpose of the July 2025 Reverse Share Split was to increase the per-share trading price of our Class A ordinary shares and to comply with Nasdaq's listing requirements.

**Corporate Information**

Our principal executive offices are located at 9 Pembroke Street Upper, Dublin D02 KR83, Ireland and our telephone number is +353 1 961 9350. We maintain websites at www.fusion-fuel.eu, www.qualityindustrialcorp.com and https://alsholagas.ae. Information available on our websites is not incorporated by reference in and is not deemed a part of this prospectus.

**The Offering**

---

| | |
|:---|:---|
| Class A Ordinary Shares outstanding (as of August 5, 2025)<sup>(1)</sup> | 1,810,567 Class A Ordinary Shares |
| Class A Ordinary Shares outstanding after giving effect to the issuance of the shares registered hereunder | 4,785,768 Class A Ordinary Shares |
| Use of Proceeds: | We are registering the Registrable Securities pursuant to the July 2025 Securities Purchase Agreement and the resale registration provisions contained therein. Accordingly, we are not selling any securities under this prospectus and will not receive any proceeds from the sale of any Registrable Securities. Notwithstanding the foregoing, we may receive proceeds upon any cash exercise of the July 2025 Warrants. If all such warrants were exercised for cash at their respective exercise prices on the date of this prospectus, we would receive aggregate gross proceeds of approximately $15,985,091. We intend to use such proceeds, if and when received, for working capital and general corporate purposes. See "*Use of Proceeds*" for more information.<br>|
| Risk Factors: | Investing in the Class A Ordinary Shares involves a high degree of risk. As an investor, you should be able to bear a complete loss of your investment. You should carefully consider the information set forth in the "*Risk Factors*" section of this prospectus, and in the "*Risk Factors*" section in any applicable prospectus supplement, post-effective amendment, or free writing prospectus, if any, and any document incorporated by reference herein or therein, before deciding to purchase any Registrable Securities from the Selling Shareholders. |
| Trading market and symbol: | The Class A Ordinary Shares and the Company's public warrants are listed on The Nasdaq Capital Market tier of Nasdaq under the symbol "HTOO" and "HTOOW", respectively. |

---

(1) The number of Class A Ordinary Shares outstanding is based on 1,810,567 Class A Ordinary Shares outstanding as of August 5, 2025, and excludes the following securities as of such date:

● 1,191,812 Class A Ordinary Shares issuable upon exercise of outstanding Series A Convertible Preferred Shares with a nominal value of $0.0001 each ("Series A Preferred Shares");

● 3,560,877 Class A Ordinary Shares issuable upon exercise of outstanding warrants;

● 2,208 Class A Ordinary Shares issuable upon exercise of outstanding restricted stock units; and

● 50,398 Class A Ordinary Shares issuable upon exercise of outstanding options.

**RISK FACTORS**

An investment in the Class A Ordinary Shares involves a high degree of risk. You should carefully consider the information set forth under Item 3.D. "Risk Factors" of the Company's Annual Report on [Form 20-F](https://www.sec.gov/Archives/edgar/data/1819794/000121390025041617/ea0240743-20f_fusion.htm) for the fiscal year ended December 31, 2024 filed with the SEC on May 9, 2025, which is incorporated by reference herein except to the extent that the risk factors stated therein are amended, restated or updated hereby, and in other filings we make with the SEC, before purchasing the Class A Ordinary Shares. The risks and uncertainties we have described are not the only ones we face. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also affect our operations.

**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**

This prospectus contains or may incorporate by reference, and any prospectus supplement or documents incorporated by reference herein or therein may contain or incorporate by reference, forward-looking statements within the meaning of Section 21E of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), and Section 27A of the U.S. Securities Act of 1933, as amended (the "Securities Act"), that are based on our management's beliefs and assumptions and on information available to us on the date of such statements. All statements other than statements of historical facts are forward-looking statements. These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

● our goals and growth strategies;

● our future prospects and market acceptance of products and services;

● our future business development, financial condition and results of operations;

● changes in our revenue, costs or expenditures;

● our expectations regarding the demand for, and market acceptance of, our products and services;

● general economic and business conditions in the markets in which we operate;

● growth and competition in the markets in which we operate;

● relevant government policies and regulations relating to our business and industry;

● our ability to obtain additional financing when and if needed; and

● the assumptions underlying or related to any of the foregoing.

In some cases, you can identify forward-looking statements by terms such as "may," "could," "will," "should," "would," "expect," "plan," "intend," "anticipate," "believe," "estimate," "predict," "potential," "project" or "continue" or the negative of these terms or other comparable terminology. These statements are only predictions. Factors that may cause actual results to differ materially from current expectations include, among other things, those referred to under the heading "*Risk Factors*" and elsewhere in this prospectus, the other documents incorporated by reference herein and under a similar heading in any applicable prospectus supplement, and the risks detailed from time to time in our future SEC reports or registration statements. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this prospectus and any applicable prospectus supplement and documents incorporated by reference herein relate only to events or information as of the date they are made. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

**USE OF PROCEEDS**

We are registering the Registrable Securities pursuant to the July 2025 Securities Purchase Agreement and the resale registration provisions contained therein. Accordingly, we are not selling any securities under this prospectus and will not receive any proceeds from the sale of any Registrable Securities. Notwithstanding the foregoing, we may receive proceeds upon any cash exercise of the July 2025 Warrants. If all such warrants were exercised for cash at their respective exercise prices on the date of this prospectus, we would receive aggregate gross proceeds of approximately $15,985,091. We intend to use such proceeds, if and when received, for working capital and general corporate purposes. Notwithstanding the foregoing, as of the date of this prospectus, we cannot specify with certainty all of the particular uses, and the respective amounts we may allocate to those uses, for any net proceeds we receive from any exercise of the July 2025 Warrants. Accordingly, we will retain broad discretion over the use of these proceeds.

The July 2025 Warrants also provide for exercise on a cashless basis if there is no effective registration statement registering, or the prospectus is not available for, the resale of Class A Ordinary Shares underlying the respective July 2025 Warrants. To the extent that the July 2025 Warrants are exercised on a cashless basis, we would not receive any proceeds from such exercise.

Under the Stock Purchase Agreement, dated as of November 18, 2024 (the "QIND Purchase Agreement"), among the Company, Quality Industrial Corp., a Nevada corporation ("QIND"), Ilustrato Pictures International Inc., a Nevada corporation, and certain other stockholders of QIND, the Company is required to use commercially reasonable efforts to raise at least $5,000,000 in one or more financing transactions ("Purchaser Financing"). 50% of the proceeds from the Purchaser Financing will be set aside and made available expressly for QIND to use for its working capital and corporate needs and the remaining 50% of such funds will be set aside and made available expressly for the businesses of the Company existing immediately prior to the closing under the QIND Purchase Agreement to use for their working capital and corporate needs. To split the net proceeds of the Purchaser Financing as described above, the Company is required to make loans of one-half of the net proceeds (or such lesser amount as agreed to by the parties in writing) to QIND, which loans will be (i) forgiven upon the conversion of the Series A Preferred Shares or (ii) repaid if the transactions contemplated by the QIND Purchase Agreement are unwound in accordance with the terms of the QIND Purchase Agreement. The Company and QIND are required to cooperate to structure such allocation of proceeds and the use of such proceeds on a mutually agreeable basis. The Company is required to utilize its portion of the net proceeds of the Purchaser Financing to pay off any indebtedness for borrowed money, accounts payable and other liabilities. To the extent that any proceeds received from the cash exercise of the July 2025 Warrants are subject to the requirements of the Purchaser Financing, then they will be required to be used in accordance with the requirements described above.

The Selling Shareholders will pay any underwriting discounts and commissions and expenses incurred by them for brokerage, accounting, tax or legal services or any other expenses incurred by them in disposing of the shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the Registrable Securities covered by this prospectus, including, without limitation, all registration and filing fees and fees and expenses of our counsel and our accountants. See "*Plan of Distribution*".

**DIVIDEND POLICY**

We have never declared or paid cash dividends on our Class A Ordinary Shares. We currently intend to retain all available funds and any future earnings for use in the operation of our business and do not anticipate paying any cash dividends on our Class A Ordinary Shares in the near future. We may also enter into credit agreements or other agreements or arrangements in the future that will restrict our ability to declare or pay cash dividends on our Class A Ordinary Shares. Any future determination to declare dividends will be made at the discretion of our board of directors and will depend on our financial condition, operating results, capital requirements, contractual restrictions, general business conditions and other factors that our board of directors may deem relevant.

**JULY 2025 PRIVATE PLACEMENT**

On July 22, 2025, the Company entered into the July 2025 Securities Purchase Agreement with the Selling Shareholders, pursuant to which the Company issued and sold the July 2025 Securities in exchange for an aggregate of $4,300,000.

In connection with the Company's entry into the July 2025 Securities Purchase Agreement, the Company also entered into a Notes Redemption, Warrants Cancellation and Exchange, Limited Waiver, Consent and Release Agreement, dated as of July 22, 2025, between the Company and each of certain investors. See "*Redemption Agreements*" below.

**July 2025 Securities Purchase Agreement**

Under the July 2025 Securities Purchase Agreement, the Company issued and sold to the Selling Shareholders: (i) the 269,459 SPA Shares, (ii) the Pre-Funded Warrants to purchase an aggregate of 541,706 Class A Ordinary Shares, (iii) the Market Price Warrants to purchase an aggregate of 1,622,330 Class A Ordinary Shares, and (iv) the 200% Warrants to purchase an aggregate of 811,165 Class A Ordinary Shares, for aggregate gross proceeds of $4,300,000. Each of the Selling Shareholders paid a purchase price equal to $5.3010 multiplied by the number of SPA Shares and/or Pre-Funded Warrant Shares underlying the Pre-Funded Warrant that they purchased, less the nominal value of the Class A Ordinary Shares multiplied by the number of Pre-Funded Warrant Shares underlying any such Pre-Funded Warrant. Each of the Selling Shareholders received a Market Price Warrant exercisable for 200% of the total number of purchased SPA Shares and the Pre-Funded Warrant Shares underlying any respective purchased Pre-Funded Warrant at an exercise price of $4.926 per share, and a 200% Warrant exercisable for 100% of the number of purchased SPA Shares and the Pre-Funded Warrant Shares underlying any respective purchased Pre-Funded Warrant at an exercise price of $9.852 per share.

The July 2025 Securities Purchase Agreement required the Company to use the net proceeds from the sale of the SPA Shares and the July 2025 Warrants to repay in full any indebtedness owed pursuant to each Senior Convertible Note, dated as of January 10, 2025, issued by the Company, and each Senior Convertible Note, dated as of March 3, 2025, issued by the Company (collectively, the "2025 Notes")., with any balance remaining to be used for general corporate and working capital purposes and to pay any fees and expenses in connection with the transactions contemplated by the July 2025 Securities Purchase Agreement.

In addition, prior to the closing under the July 2025 Securities Purchase Agreement, the Company was required to obtain (i) a written waiver from each holder of the 2025 Notes of any participation rights, pre-emptive rights, or similar rights that would otherwise apply to the transactions contemplated by the July 2025 Securities Purchase Agreement, and (ii) an acknowledgment from each holder of the 2025 Notes that the antidilution provisions contained in any outstanding Company warrants held by each holder of the 2025 Notes shall not be applicable to the transactions contemplated by the July 2025 Securities Purchase Agreement. See "*Redemption Agreements*" below.

Pursuant to the July 2025 Securities Purchase Agreement, we were required to file the registration statement of which this prospectus forms a part covering the resale of all of the Registrable Securities within 15 calendar days following the date of the issuance of the SPA Shares, which was July 25, 2025 (the "Closing Date"), and to use commercially reasonable efforts to have such registration statement declared effective within 90 days of the Closing Date. At such time that the SEC notifies us that it will not review the registration statement or has no comments, we must cause such registration statement to be declared effective within five trading days of such notification. We are required to maintain the effectiveness of such registration statement for so long as any Registrable Securities remain outstanding and are not freely tradable without restriction under Rule 144 promulgated under the Securities Act ("Rule 144").

If we (i) had not filed the registration statement of which this prospectus forms a part by the required filing date, (ii) do not cause such registration statement to be declared effective by the required effectiveness date, or (iii) do not maintain the effectiveness of the registration statement such that the Selling Shareholders are unable to use the prospectus to resell the Registrable Securities for more than 30 consecutive calendar days or more than 60 calendar days in the aggregate during any 12-month period, we will be required to pay each of the Selling Shareholders liquidated damages equal to 1.5% of its subscription amount for each 30-day period (pro-rated for partial periods) during which the failure remains uncured. These liquidated damages accrue and are payable on a daily basis, without the need for demand or notice. If we fail to make any such payment when due, we will be required to pay interest on the overdue amount at a rate of 18% per annum (or, if lower, the maximum rate permitted by law), accruing daily until paid in full. These obligations survive any termination of the July 2025 Securities Purchase Agreement and are in addition to any other rights or remedies available to the Selling Shareholders.

In addition, we were required to reimburse the Selling Shareholders for out-of-pocket costs and expenses (including reasonable attorneys' fees of one of the Selling Shareholders and/or its affiliates of up to $65,000) incurred in connection with the July 2025 Private Placement, including the resale of the Registrable Securities and the filing, registration, and effectiveness of the registration statement of which this prospectus forms a part.

The January 2025 Purchase Agreement also contains customary closing conditions, representations and warranties, covenants, and indemnification provisions. The offer and sale of securities described above was conducted as a private placement pursuant to and in reliance on the exemption from registration provided by Section 4(a)(2) of the Securities Act and/or Rule 506(b) of Regulation D promulgated thereunder for transactions not involving a public offering.

**July 2025 Warrants**

See "*Description of Securities – July 2025 Warrants*" for a description of the July 2025 Warrants.

**Redemption Agreements**

On July 22, 2025, as a condition to the closing of the July 2025 Private Placement, we entered into a certain Notes Redemption, Warrants Cancellation and Exchange, Limited Waiver, Consent and Release Agreement, dated as of July 22, 2025 (collectively, the "Redemption Agreements"), between the Company and each holder of the 2025 Notes (collectively, the "Note Investors"). Pursuant to the Redemption Agreements, the Company agreed to redeem each of the 2025 Notes, to the extent not previously converted or repaid, upon or within one business day after the closing under the July 2025 Securities Purchase Agreement. The Redemption Agreements provide that upon receipt of the redemption price, the Note Investors were required to surrender the 2025 Notes for cancellation, and all rights and obligations under the 2025 Notes will terminate. In connection with the prior conversion in full of the 2025 Notes on or around July 22, 2025, the redemption price under each of the Redemption Agreements was $0.

Pursuant to the Redemption Agreements, the Note Investors waived and released claims relating to certain rights, restrictions, and conditions under the Securities Purchase Agreement, dated as of January 10, 2025, between the Company and certain of the Note Investors, and the Securities Purchase Agreement, dated as of February 28, 2025, between the Company and certain of the Note Investors (together the "2025 Notes Purchase Agreements"), with respect to any Subsequent Placements (as defined in the 2025 Notes Purchase Agreements), redemptions, cash dividends, share splits, reverse share splits, and any other subsequent transactions of the Company, and omissions from performing any remaining post-closing conditions under the 2025 Notes Purchase Agreements, without being subject to any price-based antidilution adjustments, resets, or similar effects, participation rights, or cash payment requirements upon changes of control, including any change of control redemption rights (the "2025 Notes Waived Matters"). In addition, the Note Investors waived and released claims relating to the requirement for the Company to make certain payments from proceeds of the Company's at-the-market offering to the Note Investors under each Limited Waiver or Amended and Restated Limited Waiver, dated as of March 26, 2025, between the Company and the respective Note Investor.

The Redemption Agreements further provide for the cancellation of each of the warrants previously issued to the Note Investors on January 10, 2025 and March 3, 2025 (the "Prior 2025 Warrants"), and the exchange of the Prior 2025 Warrants for new warrants to purchase Class A Ordinary Shares (the "Exchanged 2025 Warrants"), pursuant to Section 3(a)(9) under the Securities Act. See "*Description of Securities – Exchanged 2025 Warrants*" for a description of the Exchanged 2025 Warrants.

In addition, each of the Redemption Agreements includes a "most favored nations" provision that no other Note Investor will receive more favorable terms under any of the Redemption Agreements, and if more favorable terms are provided to any of the Note Investors under any of the Redemption Agreements, the other Note Investors will automatically receive the benefit of such terms unless the Note Investors elect otherwise.

**DESCRIPTION OF SECURITIES**

A description of our securities is included in [Exhibit 2.13](https://www.sec.gov/Archives/edgar/data/1819794/000121390025041617/ea024074301ex2-13_fusion.htm) to the Annual Report on Form 20-F for the fiscal year ended December 31, 2024 filed with the SEC on May 9, 2025, which is incorporated by reference herein, and supplemented as follows.

**July 2025 Warrants**

***Pre-Funded Warrants***

*Exercise Price.* The Pre-Funded Warrants are exercisable for cash at a nominal exercise price of $0.0035 per Class A Ordinary Share, subject to certain customary adjustments.

 

*Exercise Period.* The Pre-Funded Warrants are exercisable at any time from the initial issuance date until the Pre-Funded Warrant is exercised in full. There is no fixed expiration date; the warrants remain outstanding until fully exercised.

 

*Limitations on Exercise.* Each of the Pre-Funded Warrant holders may not exercise any portion of the Pre-Funded Warrants to the extent that, after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of the 2025 Warrants Beneficial Ownership Limitation, which is initially set at 4.99% of the outstanding Class A Ordinary Shares but which may be increased or decreased by the holder to any percentage not in excess of 9.99%, with any increase only becoming effective upon 61 days' prior written notice to us.

***Market Price Warrants***

*Exercise Price.* The Market Price Warrants are initially exercisable at an exercise price of $4.926 per Class A Ordinary Share, subject to certain customary adjustments.

*Exercise Period.* The Market Price Warrants are exercisable at any time during the three-year period beginning on their original issue date and ending July 25, 2028.

*Limitations on Exercise.* Each of the Market Price Warrant holders may not exercise any portion of the Market Price Warrants to the extent that, after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of the 2025 Warrants Beneficial Ownership Limitation, which is initially set at 4.99% of the outstanding Class A Ordinary Shares but which may be increased or decreased by the holder to any percentage not in excess of 9.99%, with any increase only becoming effective upon 61 days' prior written notice to us.

***200% Market Price Warrants***

*Exercise Price.* The 200% Market Price Warrants are initially exercisable at an exercise price of $9.852 per Class A Ordinary Share, subject to certain customary adjustments.

*Exercise Period.* The 200% Market Price Warrants are exercisable at any time during the three-year period beginning on their original issue date and ending July 25, 2028.

*Limitations on Exercise.* Each of the 200% Market Price Warrant holders may not exercise any portion of the 200% Market Price Warrants to the extent that, after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of the 2025 Warrants Beneficial Ownership Limitation, which is initially set at 4.99% of the outstanding Class A Ordinary Shares but which may be increased or decreased by the holder to any percentage not in excess of 9.99%, with any increase only becoming effective upon 61 days' prior written notice to us.

**Exchanged 2025 Warrants**

*Exercise Price.* The Exchanged 2025 Warrants are initially exercisable at a price per share equal to $5.78, subject to certain customary adjustments.

*Exercise Period*. The Exchanged 2025 Warrants issued in exchange for the cancellation of the January 2025 Warrants are exercisable at any time until January 10, 2028. The Exchanged 2025 Warrants issued in exchange for the cancellation of the March 2025 Warrants are exercisable at any time until March 3, 2028.

*Limitations on Exercise.* Each of the Exchanged 2025 Warrant holders may not exercise any portion of the Exchanged 2025 Warrants to the extent that, after giving effect to such exercise, the holder (together with its affiliates) would beneficially own in excess of the 2025 Warrants Beneficial Ownership Limitation, which is initially set at 4.99% of the outstanding Class A Ordinary Shares but which may be increased or decreased by the holder to any percentage not in excess of 9.99%, with any increase only becoming effective upon 61 days' prior written notice to us.

**SELLING SHAREHOLDERS**

This prospectus covers the resale or other disposition by the Selling Shareholders of the Registrable Securities. The Selling Shareholders listed in the table below may from time to time offer and sell any or all of the Registrable Securities set forth below pursuant to this prospectus. When we refer to the "Selling Shareholders" in this prospectus, we refer to the persons listed in the table below and the permitted transferees that hold any of the Selling Shareholders' interest in Registrable Securities after the date of this prospectus.

The following table sets forth certain information concerning the Registrable Securities that may be offered from time to time by each Selling Shareholder pursuant to this prospectus. The number of Registrable Securities beneficially owned by each Selling Shareholder has been determined in accordance with SEC rules, which deem a person to own any shares over which the person has sole or shared voting or investment power. Percentage ownership is based on 1,810,567 Class A Ordinary Shares outstanding as of August 5, 2025. In calculating the number of shares beneficially owned by, and the percentage ownership of, any person, we treat as outstanding the July 2025 Warrant Shares that are currently exercisable even though those shares are not deemed outstanding when computing the percentage ownership of any other person. The percentages shown in the table reflect the 2025 Warrants Beneficial Ownership Limitation, which generally limits each holder (together with its affiliates) to beneficial ownership of no more than 4.99% of the outstanding Class A Ordinary Shares (subject to a holder-elected increase to 9.99% upon 61 days' prior written notice). Except as otherwise indicated, and subject to applicable community-property laws, we believe that each Selling Shareholder listed in the table exercises sole voting and investment power over the shares shown as beneficially owned.

The Selling Shareholders identified below may have sold, transferred or otherwise disposed of all or a portion of their securities included in the table below in transactions exempt from the registration requirements of the Securities Act. Any changed or new information provided to us by the Selling Shareholders, including regarding the identity of, and the securities held by, each of the Selling Shareholder, will be set forth in a prospectus supplement or amendments to the registration statement of which this prospectus forms a part, if and when necessary. A Selling Shareholder may sell all, some or none of such securities in this offering. See "*Plan of Distribution*". For purposes of this table, we have assumed that the Selling Shareholders will have sold all of the securities covered by this prospectus upon the completion of the offering.

The Selling Shareholders do not have, and within the past three years have not had, any position, office or other material relationship with us.

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name of Selling Shareholder** | **Class A Ordinary Shares Owned Prior to Offering<sup>(1)</sup>** |  | **Beneficial Ownership (%)** | **Maximum Class A Ordinary Shares Offered Hereby** |  | **Class A Ordinary Shares Owned After Offering<sup>(2)</sup>** | **Beneficial Ownership (%)** |
| Lantern Management Fund LP<sup>(3)</sup> | 91151 | (4) | 4.99% | 1803432 | (5) | – |  |
| Bower Four Capital Corp.<sup>(6)</sup> | 91151 | (7) | 4.99% | 697980 | (8) | – |  |
| Roxy Capital Corporation<sup>(9)</sup> | 91151 | (10) | 4.99% | 565928 | (11) | – |  |
| BCL Sunset, LLC<sup>(12)</sup> | 93606 | (13) | 4.99% | 113184 | (14) | – |  |
| Samuel Dorf<sup>(15)</sup> | 56592 | (16) | 2.31% | 56592 | (17) | – |  |
| James Allan<sup>(18)</sup> | 7544 | (19) | \* | 7544 | (20) | – |  |

---

\* Represents beneficial ownership of less than 1% of our outstanding Class A Ordinary Shares.

(1) Beneficial
 ownership prior to this offering is based on 1,810,567 Class A Ordinary Shares outstanding
 as of August 5, 2025 and 4,785,768 Class A Ordinary Shares outstanding after this
 offering assuming the sale of all Registrable Securities offered hereby.

(2) Assumes
 the sale of all shares being offered pursuant to this prospectus.

(3) Lantern
 Management Fund GP ("Lantern GP") is the general partner of Lantern Management
 Fund LP ("Lantern LP"). Voting and investment decisions with respect to the
 securities held by Lantern LP are made by the investment committee of Lantern GP, which is
 comprised of three members and acts by majority vote. The principal address of the
 foregoing entities is CO SERVICES CAYMAN LIMITED, Willow House,
 Cricket Square, Grand Cayman KY1 1001, Cayman Islands.

(4) Consists
 of 75,043 Class A Ordinary Shares and an aggregate of 16,108 Class A Ordinary Shares issuable
 upon exercise of this Selling Shareholder's Pre-Funded Warrant, Market Price Warrant,
 and 200% Price Warrant, after giving effect to the 2025 Warrants Beneficial Ownership Limitation.
 Without giving effect to the 2025 Warrants Beneficial Ownership Limitation, within 60 days
 of August 5, 2025 this Selling Shareholder would beneficially own an aggregate of 1,803,432
 Class A Ordinary Shares, consisting of (i) 75,043 Class A Ordinary Shares, (ii) 375,815 Class
 A Ordinary Shares issuable upon exercise of a Pre-Funded Warrant, (iii) 901,716 Class A Ordinary
 Shares issuable upon exercise of a Market Price Warrant and (iv) 450,858 Class A Ordinary
 Shares issuable upon exercise of 200% Price Warrant.

(5) Consists
 of (i) 75,043 Class A Ordinary Shares, (ii) 375,815 Class A Ordinary Shares issuable upon
 exercise of a Pre-Funded Warrant, (iii) 901,716 Class A Ordinary Shares issuable upon exercise
 of a Market Price Warrant and (iv) 450,858 Class A Ordinary Shares issuable upon exercise
 of 200% Price Warrant, in each case without regard to the 2025 Warrants Beneficial Ownership
 Limitation.

(6) Gregory
 Lipschitz holds sole voting and investment power over all Registrable Securities owned by
 Bower Four Capital Corp. The principal address of Bower Four Capital Corp.
 is 104 One Cable Beach, Nassau, Bahamas.

(7) Consists
 of 75,043 Class A Ordinary Shares and an aggregate of 16,108 Class A Ordinary Shares issuable
 upon exercise of this Selling Shareholder's Pre-Funded Warrant, Market Price Warrant,
 and 200% Price Warrant, after giving effect to the 2025 Warrants Beneficial Ownership Limitation.
 Without regard to the 2025 Warrants Beneficial Ownership Limitation, within 60 days of August
 5, 2025 this Selling Shareholder would beneficially own an aggregate of 697,980 Class A
 Ordinary Shares, consisting of (i) 75,043 Class A Ordinary Shares, (ii) 99,452 Class A Ordinary
 Shares issuable upon exercise of a Pre-Funded Warrant, (iii) 348,990 Class A Ordinary Shares
 issuable upon exercise of a Market Price Warrant, and (iv) 174,495 Class A Ordinary Shares
 issuable upon exercise of a 200% Price Warrant.

(8) Consists
 of (i) 75,043 Class A Ordinary Shares, (ii) 99,452 Class A Ordinary Shares issuable upon
 exercise of a Pre-Funded Warrant, (iii) 348,990 Class A Ordinary Shares issuable upon exercise
 of a Market Price Warrant, and (iv) 174,495 Class A Ordinary Shares issuable upon exercise
 of a 200% Price Warrant, in each case without regard to the 2025 Warrants Beneficial Ownership
 Limitation.

(9) Eric Lazer
 holds sole voting and investment power over all Registrable Securities owned by Roxy Capital Corporation.
 The principal address of Roxy Capital Corporation is 20 Canal Beach,
 Old Fort Bay, P.O. Box N7776, Nassau, Bahamas 00000.

(10) Consists
 of 75,043 Class A Ordinary Shares and an aggregate of 16,108 Class A Ordinary Shares issuable
 upon exercise of this Selling Shareholder's Pre-Funded Warrant, Market Price Warrant,
 and 200% Price Warrant, after giving effect to the 2025 Warrants Beneficial Ownership Limitation.
 Without regard to the 2025 Warrants Beneficial Ownership Limitation, within 60 days of August
 5, 2025 this Selling Shareholder would beneficially own an aggregate of 565,928 Class A
 Ordinary Shares, consisting of (i) 75,043 Class A Ordinary Shares, (ii) 66,439 Class A Ordinary
 Shares issuable upon exercise of a Pre-Funded Warrant, (iii) 282,964 Class A Ordinary Shares
 issuable upon exercise of a Market Price Warrant, and (iv) 141,482 Class A Ordinary Shares
 issuable upon exercise of a 200% Price Warrant.

(11) Consists
 of (i) 75,043 Class A Ordinary Shares, (ii) 66,439 Class A Ordinary Shares issuable upon
 exercise of a Pre-Funded Warrant, (iii) 282,964 Class A Ordinary Shares issuable upon exercise
 of a Market Price Warrant, and (iv) 141,482 Class A Ordinary Shares issuable upon exercise
 of a 200% Price Warrant, in each case without regard to the 2025 Warrants Beneficial Ownership
 Limitation.

(12) Constantine
 Karides holds sole voting and investment power over all Registrable Securities owned by BCL Sunset, LLC.
 The principal address of BCL Sunset, LLC is 2767 Sunset Drive, Miami Beach, FL
 33140.

(13) Consists
 of 28,296 Class A Ordinary Shares and an aggregate of 65,310 Class A Ordinary Shares issuable
 upon exercise of this Selling Shareholder's Market Price Warrant and 200% Price Warrant,
 after giving effect to the 2025 Warrants Beneficial Ownership Limitation. Without regard
 to the 2025 Warrants Beneficial Ownership Limitation, within 60 days of August 5, 2025,
 this Selling Shareholder would beneficially own an aggregate of 113,184 Class A Ordinary
 Shares, consisting of (i) 28,296 Class A Ordinary Shares, (i) 56,592 Class A Ordinary Shares
 issuable upon exercise of a Market Price Warrant, and (iii) 28,296 Class A Ordinary Shares
 issuable upon exercise of a 200% Price Warrant.

(14) Consists
 of (i) 28,296 Class A Ordinary Shares, (i) 56,592 Class A Ordinary Shares issuable upon exercise
 of a Market Price Warrant, and (iii) 28,296 Class A Ordinary Shares issuable upon exercise
 of a 200% Price Warrant, in each case without regard to the 2025 Warrants Beneficial Ownership
 Limitation.

(15) The
 principal address of Samuel Dorf is 1009 N. Dearborn St, Chicago, Illinois
 60611.

(16) Consists
 of (i) 14,148 Class A Ordinary Shares, (ii) 28,296 Class A Ordinary Shares issuable upon
 exercise of a Market Price Warrant, and (iii) 14,148 Class A Ordinary Shares issuable upon
 exercise of a 200% Price Warrant.

(17) Consists
 of (i) 14,148 Class A Ordinary Shares, (ii) 28,296 Class A Ordinary Shares issuable upon
 exercise of a Market Price Warrant, and (iii) 14,148 Class A Ordinary Shares issuable upon
 exercise of a 200% Price Warrant.

(18) The
 principal address of James Allan is Cube 1A, Albany Resort, 127 S Ocean Road,
 New Providence, Bahamas.

(19) Consists
 of (i) 1,886 Class A Ordinary Shares, (ii) 3,772 Class A Ordinary Shares issuable upon exercise
 of a Market Price Warrant, and (iii) 1,886 Class A Ordinary Shares issuable upon exercise
 of a 200% Price Warrant.

(20) Consists
 of (i) 1,886 Class A Ordinary Shares, (ii) 3,772 Class A Ordinary Shares issuable upon exercise
 of a Market Price Warrant, and (iii) 1,886 Class A Ordinary Shares issuable upon exercise
 of a 200% Price Warrant.

**PLAN OF DISTRIBUTION**

The Selling Shareholders may, from time to time, dispose of all or a portion of the Class A Ordinary Shares covered by this prospectus directly or through one or more underwriters, broker-dealers or agents. If any Class A Ordinary Shares are sold through underwriters, broker-dealers or agents, the Selling Shareholders will bear the underwriting discounts or commissions or any agent's commissions. Sales of Registrable Securities may occur in one or more transactions (which may include crosses or block trades) at fixed prices, at prevailing market prices, at prices determined at the time of sale or at negotiated prices, and may be effected by means that include:

● any national securities exchange or quotation service on which our Class A Ordinary Shares are then listed or quoted, including Nasdaq;

● the over-the-counter market;

● transactions otherwise than on these exchanges, quotation systems or the over-the-counter market;

● ordinary brokerage transactions, including transactions in which a broker-dealer solicits purchasers;

● block trades in which a broker-dealer acts as agent but may position and resell a portion of the block as principal to facilitate the transaction;

● purchases by a broker-dealer as principal and resale by the broker-dealer for its own account;

● an exchange distribution in accordance with the rules of the applicable exchange;

● privately negotiated transactions;

● short sales, including the settlement of short sales and the delivery of Registrable Securities to close out short positions or return borrowed shares;

● transactions executed through broker-dealers that agree with a Selling Shareholder to sell a specified number of Registrable Securities at a stipulated price per share;

● the writing or settlement of options, swaps, caps, collars, forward-sale contracts or other hedging or derivative transactions, whether such instruments are listed on an options exchange or traded privately;

● to or through one or more underwriters or dealers in a public offering, whether individually or through an underwriting syndicate led by one or more managing underwriters;

● through agents acting on a best-efforts basis for the period of their appointment;

● a combination of any of the foregoing methods; or

● any other method permitted by applicable law.

The Selling Shareholders may also sell Registrable Securities pursuant to Rule 144 or another exemption from registration under the Securities Act, if available, rather than under this prospectus, and may transfer Registrable Securities by other means not described herein. They may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short sales of the Registrable Securities, or they may loan, pledge or otherwise encumber such securities; upon a default, the pledgees or secured parties may offer and sell the pledged Registrable Securities as Selling Shareholders under this prospectus.

If underwriters participate in the sale of any Registrable Securities, such registrable securities will be acquired by the underwriters for their own accounts and may be resold in one or more of the transactions described above. Registrable Securities may be offered to the public through underwriting syndicates represented by managing underwriters or directly by one or more underwriters. If a dealer is used, the dealer may purchase the shares as principal and resell them at prices determined by the dealer at the time of resale. We will identify each underwriter, dealer, or agent in the applicable prospectus supplement and describe any compensation, discounts or commissions they receive. Any such underwriters, dealers, or agents may be deemed to be "underwriters" within the meaning of the Securities Act, and any discounts, concessions, or commissions they receive and any profit they realize on resale of the shares may be deemed to be underwriting discounts or commissions.

Underwriters, dealers and agents may be entitled to indemnification or contribution from the Selling Shareholders and/or us against certain civil liabilities, including liabilities under the Securities Act.

The Selling Shareholders and any other persons participating in the distribution of Registrable Securities will be subject to the provisions of the Exchange Act and its regulations, including Regulation M, which may restrict certain activities and affect the marketability of the shares. In particular, persons engaged in the distribution may not simultaneously engage in market-making activities with respect to the Registrable Securities for the applicable restricted period. We have provided each Selling Shareholder with a copy of this prospectus and informed them of the need to deliver a copy of this prospectus, as supplemented or amended, to each purchaser at or prior to the time of sale in compliance with Rule 172 under the Securities Act.

We agreed to reimburse the Selling Shareholders for out-of-pocket costs and expenses (including reasonable attorneys' fees of one of the Selling Shareholders and/or its affiliates of up to $65,000) incurred in connection with the July 2025 Private Placement, including the resale of the Registrable Securities and the filing and registration of the registration statement of which this prospectus forms a part. We are also responsible for transfer agent fees, DTC fees, and broker's commissions related to the transactions, and have agreed to indemnify the Selling Shareholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act relating to this prospectus and the registration statement of which it forms a part.

We have agreed to keep the registration statement of which this prospectus forms a part effective until all Registrable Securities covered hereby have been sold pursuant to this prospectus or may be sold without restriction under Rule 144 or are no longer outstanding.

Our Class A Ordinary Shares and public warrants trade on Nasdaq under the symbols "HTOO" and "HTOOW," respectively. Once sold under this prospectus, the Registrable Securities will be freely tradable by persons other than our affiliates, subject to applicable securities laws.

**EXPENSES RELATED TO THE OFFERING**

Set forth below is an itemization of the total expenses that are expected to be incurred by us in connection with the Registrable Securities being registered for resale hereby and the offer and sale of the Registrable Securities by the Selling Shareholders. With the exception of the SEC registration fee, all amounts are estimates.

---

| | |
|:---|:---|
|  | **Amount** |
| SEC registration fee | $3095.67 |
| Legal fees and expenses | 100000 |
| Accounting fees and expenses | 50000 |
| Transfer agent fees | 10000 |
| State securities and blue sky laws compliance | 2500 |
| Miscellaneous expenses | 5000 |
| **Total** | $170595.67 |

---

**LEGAL MATTERS**

Bevilacqua PLLC, Washington, D.C., is acting as counsel in connection with the registration of our securities under the Securities Act and will pass upon certain legal matters for us with respect to the offering of our securities. Arthur Cox LLP, Dublin, Ireland, will pass upon the validity of the securities offered in this prospectus and on matters of Irish law.

As of the date of this prospectus, Bevilacqua PLLC holds 7,286 Class A Ordinary Shares. Bevilacqua PLLC received these securities as partial consideration for legal services.

**EXPERTS**

The consolidated financial statements of the Company as of and for the fiscal year ended December 31, 2024 have been incorporated by reference herein and in the registration statement in reliance upon the report of Bush & Associates CPA LLC, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.

The audit report covering the consolidated financial statements of the Company as of and for the fiscal year ended December 31, 2024 contains an explanatory paragraph that states that the Company's operating losses raise substantial doubt about the entity's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

The consolidated financial statements of the Company as of December 31, 2023, and for each of the years in the two-year period ended December 31, 2023, have been incorporated by reference herein and in the registration statement in reliance upon the report of KPMG, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.

The consolidated financial statements of QIND as of December 31, 2023 and 2022, and for each of the years in the two-year period ended December 31, 2023, have been incorporated by reference herein and in the registration statement in reliance upon the report of Bush & Associates CPA LLC, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.

The audit report covering the December 31, 2023 and 2022 consolidated financial statements of QIND contains an explanatory paragraph that states that QIND's recurring losses from operations and net capital deficiency for the period ended December 31, 2023 raise substantial doubt about the entity's ability to continue as a going concern. The consolidated financial statements do not include any adjustments that might result from the outcome of that uncertainty.

**INDEMNIFICATION**

Insofar as indemnification by us for liabilities arising under the Securities Act may be permitted to our directors, officers or persons controlling the company pursuant to provisions of our constitution, or otherwise, we have been advised that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. In the event that a claim for indemnification by such director, officer or controlling person of us in the successful defense of any action, suit or proceeding is asserted by such director, officer or controlling person in connection with the securities being offered, we will, unless in the opinion of our counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by us is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**ENFORCEMENT OF CIVIL LIABILITIES**

We were incorporated under the laws of Ireland. Some of our directors and officers reside outside of the United States. Service of process upon such persons may be difficult or impossible to effect within the United States. Furthermore, because most of our assets, and some of the assets of our directors and officers, are located outside of the United States, any judgment obtained in the United States, including a judgment based upon the civil liability provisions of United States federal securities laws, against us or any of such persons may not be collectible within the United States. It also may be difficult for an investor, or any other person or entity, to assert United States securities laws claims in original actions instituted in Ireland.

In addition, it may not be possible to enforce court judgments obtained in the United States against us in Ireland based on the civil liability provisions of the U.S. federal or state securities laws. The United States currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters.

The following requirements must be met before a judgment of a U.S. court will be deemed to be enforceable in Ireland:

● the judgment must be for a definite sum;

● the judgment must be final and conclusive; and

● the judgment must be provided by a court of competent jurisdiction.

An Irish court will also exercise its right to refuse enforcement if the U.S. judgment was obtained by fraud, if the judgment violates Irish public policy, if the judgment is in breach of natural or constitutional justice or if it is irreconcilable with an earlier foreign judgment. There is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liabilities provisions of the U.S. federal or state securities laws or hear actions against us or those persons based on those laws. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically be enforceable in Ireland.

Foreign judgments enforced by Irish courts generally will be payable in euros. An Irish court hearing an action to recover an amount in a non-Irish currency will render judgment for the equivalent amount in Irish currency.

Our agent for service of process in the United States is CT Corporation System, 28 Liberty Street, New York, NY 10005, (212) 894-8940.

**MATERIAL CHANGES**

Except as otherwise disclosed in this prospectus, there have been no reportable material changes that have occurred since December 31, 2024, and that have not been described in a report on Form 6-K furnished under the Exchange Act and incorporated by reference into this prospectus.

**WHERE YOU CAN FIND MORE INFORMATION; DOCUMENTS INCORPORATED BY REFERENCE**

**Available Information**

This prospectus is part of a registration statement on Form F-3 that we filed with the SEC registering the securities that may be offered and sold hereunder. This prospectus, which constitutes a part of the registration statement, does not contain all of the information set forth in the registration statement, the exhibits filed therewith or the documents incorporated by reference therein. For further information about us and the securities offered hereby, reference is made to the registration statement, the exhibits filed therewith, and the documents incorporated by reference therein. Statements contained in this prospectus regarding the contents of any contract or any other document that is filed as an exhibit to the registration statement are not necessarily complete, and in each instance, we refer you to the copy of such contract or other document filed as an exhibit to the registration statement. We are required to file reports and other information with the SEC pursuant to the Exchange Act, including annual reports on Form 20-F and reports on Form 6-K.

The SEC maintains a website that contains reports and other information regarding issuers, like us, that file electronically with the SEC. The address of the website is www.sec.gov. The information on our website (www.fusion-fuel.eu), other than our SEC filings, is not, and should not be, considered part of this prospectus and is not incorporated by reference into this document.

As a foreign private issuer, we are exempt under the Exchange Act from, among other things, the rules prescribing the furnishing and content of proxy statements, and our officers, directors and principal shareholders are exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we are not required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act.

**Incorporation by Reference**

The SEC allows us to "incorporate by reference" the information we file with it into this prospectus. This means that we can disclose important information about us and our financial condition to you by referring you to another document filed separately with the SEC instead of having to repeat the information in this prospectus. The information incorporated by reference is considered to be part of this prospectus and later information that we file with the SEC will automatically update and supersede this information. We incorporate by reference into this prospectus the information contained in the documents listed below and any future filings made by us with the SEC under Section 13(a), 13(c) or 15(d) of the Exchange Act, except for information "furnished" to the SEC which is not deemed filed and not incorporated by reference into this prospectus (unless otherwise indicated below), until the termination of the offering of securities described in the applicable prospectus supplement:

● the Company's Annual Report on [Form 20-F](https://www.sec.gov/Archives/edgar/data/1819794/000121390025041617/ea0240743-20f_fusion.htm) for the fiscal year ended December 31, 2024, filed with the SEC on May 9, 2025;

● the Company's Reports on Form 6-K (and any amendments thereto on Form 6-K/A) furnished to the SEC on [January 3, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025000775/ea0226731-6k_fusion.htm) , [January 13, 2025](https://www.sec.gov/Archives/edgar/data/0001819794/000121390025002806/ea0227460-6k_fusion.htm) , [January 13, 2025](https://www.sec.gov/Archives/edgar/data/0001819794/000121390025002830/ea0227390-6k_fusion.htm) (other than Exhibit 99.1 thereto), [January 13, 2025](https://www.sec.gov/Archives/edgar/data/0001819794/000121390025002838/ea0227392-6k_fusion.htm) (other than Exhibit 99.1 thereto), [January 14, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025003420/ea0227640-6k_fusionfuel.htm) , [January 27, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025007089/ea0228717-6k_fusionfuel.htm) , [February 24, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025016628/ea0231922-6k_fusion.htm) , [February 27, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025017655/ea0232333-6k_fusion.htm) (other than Exhibit 99.1 thereto), [March 3, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025019043/ea0232651-6k_fusion.htm) , [March 10, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025022234/ea0233391-6ka1_fusion.htm) (other than Exhibit 99.7 and Exhibit 99.8 thereto), [May 12, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025042040/ea0241752-6ka2_fusion.htm) , [May 16, 2025](http://www.sec.gov/Archives/edgar/data/1819794/000121390025044951/ea0242594-6k_fusion.htm) , [July 23, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066971/ea0250030-6k_fusion.htm) (other than Exhibit 99.1 thereto), [June 4, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025050975/ea0244648-6k_fusion.htm) (other than Exhibit 99.2 thereto), [June 25, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025057835/ea0247009-6k_fusion.htm) (other than Exhibit 99.1 thereto), [July 10, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025062528/ea0248434-6k_fusion.htm) (other than Exhibit 99.1 thereto), [July 23, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea0249977-6k_fusion.htm) , [July 28, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000121390025068299/ea0250416-6k_fusion.htm) , [July 30, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000164117225021549/form6-k.htm) , and [August 5, 2025](https://www.sec.gov/Archives/edgar/data/1819794/000164117225022259/form6-k.htm) ; and

● the description of the Company's securities contained in the Company's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/0001819794/000121390020041851/ea131356-8a12b_fusionfuel.htm) (File No. 001-39789) filed with the SEC on December 9, 2020, pursuant to Section 12(b) of the Exchange Act, including any amendment or report filed for the purpose of updating such description.

We also incorporate by reference any future annual reports on Form 20-F we file with the SEC under the Exchange Act after the date of this prospectus and prior to the termination of the offering of securities by means of this prospectus, and any future reports of foreign private issuer on Form 6-K we furnish with the SEC during such period that are identified in such reports as being incorporated by reference into this prospectus.

Any reports filed by us with the SEC after the date of this prospectus and before the date that the offering of securities by means of this prospectus is terminated will automatically update and, where applicable, supersede any information contained in this prospectus or incorporated by reference in this prospectus. This means that you must look at all of the SEC filings that we incorporate by reference to determine if any of the statements in this prospectus or in any documents incorporated by reference have been modified or superseded. Unless expressly incorporated by reference, nothing in this prospectus shall be deemed to incorporate by reference information furnished to, but not filed with, the SEC.

We will provide without charge to any person (including any beneficial owner) to whom this prospectus is delivered, upon oral or written request, a copy of any document incorporated by reference in this prospectus but not delivered with the prospectus (except for exhibits to those documents unless a document states that one of its exhibits is incorporated into the document itself). Such request should be directed to: Fusion Fuel Green PLC, 9 Pembroke Street Upper, Dublin D02 KR83, Ireland, and telephone number +353 1 961 9350.

**PART II**

**INFORMATION NOT REQUIRED IN THE PROSPECTUS**

*Unless the context indicates otherwise, "we," "us," "our," "the Company," and similar references in this* Part II. "Information Not Required in the Prospectus" *refer to the operations of Fusion Fuel Green PLC, an Irish public limited company.*

**Item 8. Indemnification of Directors and Officers**

Pursuant to the Company's constitution, subject to the provisions of and so far as may be permitted by the Companies Act 2014 of Ireland (the "Company Act"), every person who is or was a director, officer or employee of the Company, and each person who is or was serving at the request of the Company as a director, officer or employee of another company, or of a partnership, joint venture, trust or other enterprise, shall be entitled to be indemnified by the Company against all costs, charges, losses, expenses and liabilities incurred by him or her in the execution and discharge of his or her duties or in relation thereto, including any liability incurred by him or her in defending any proceedings, civil or criminal, which relate to anything done or omitted or alleged to have been done or omitted by him or her as a director, officer or employee of the Company or such other company, partnership, joint venture, trust or other enterprise, and in which judgment is given in his or her favor (or the proceedings are otherwise disposed of without any finding or admission of any material breach of duty on his or her part) or in which he or she is acquitted or in connection with any application under any statute for relief from liability in respect of any such act or omission in which relief is granted to him or her by the court.

The Companies Act prescribes that such an indemnity only permits a company to indemnify any officer against any liability incurred by him or her (i) in defending proceedings where judgment is given in any civil or criminal action in his or her favor or in which he or she is acquitted, (ii) in connection with any proceedings for negligence, default, breach of duty or breach of trust against the officer where an Irish court grants relief because it appears to the court that the officer in question is or may be liable in respect of the negligence, default, breach of duty or breach of trust but that he or she acted honestly and reasonably and should therefore be granted relief from such liability or (iii) in connection with an application made by the officer to be relieved of liability in respect of a claim that the officer apprehends will be made against him or her in respect of any negligence, default, breach of duty or breach of trust, if such relief is granted to the officer by the court.

The Company is permitted under its constitution and the Companies Act to purchase directors' and officers' liability insurance, as well as other types of insurance, for its directors, officers and employees.

The Company has entered into deeds of indemnity with its directors and executive officers. Given the director indemnification limitations arising under Irish law, the Company's subsidiary, Fusion Fuel Portugal, S.A. ("Fusion Fuel Portugal"), has also entered into such deeds of indemnity. These agreements, among other things, require the Company and Fusion Fuel Portugal to jointly and severally indemnify the Company's directors and executive officers as well as Fusion Fuel Portugal's directors and executive officers for certain expenses, including attorneys' fees, judgments, fines and settlement amounts incurred by any such director or executive officer in any action or proceeding arising out of their services as one of the Company's or Fusion Fuel Portugal's directors or executive officers or as a director or executive officer of any other company or enterprise to which the person provides services at the Company's or Fusion Fuel Portugal's request. We believe that these indemnification agreements are necessary to attract and retain qualified persons as directors and officers.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, the Company has been informed that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act and is theretofore unenforceable.

**Item 9. Exhibits.**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 4.1 | [Amended and Restated Constitution of Fusion Fuel Green PLC (incorporated by reference to Exhibit 1.1 to the Form 6-K filed July 10, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025062528/ea024843401ex1-1_fusion.htm) |
| 4.2 | [Specimen Class A Ordinary Share Certificate of Fusion Fuel Green PLC (incorporated by reference to Exhibit 4.1 to Registration Statement on Form F-4/A filed on October 9, 2020)](https://www.sec.gov/Archives/edgar/data/1819794/000121390020030855/ea127972ex4-1_fusionfuel.htm) |
| 4.3 | [Description of Securities (incorporated by reference to Exhibit 2.13 to Annual Report on Form 20-F filed on May 9, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025041617/ea024074301ex2-13_fusion.htm) |
| 4.4 | [Form of Pre-Funded Ordinary Shares Purchase Warrant issued on July 25, 2025 (incorporated by reference to Exhibit 4.1 to the Form 6-K filed on July 23, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex4-1_fusion.htm) |
| 4.5 | [Form of Ordinary Shares Purchase Warrant issued on July 25, 2025 (incorporated by reference to Exhibit 4.2 to the Form 6-K filed on July 23, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex4-2_fusion.htm) |
| 4.6 | [Form of Ordinary Shares Purchase Warrant issued on July 25, 2025 (incorporated by reference to Exhibit 4.3 to the Form 6-K filed on July 23, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex4-3_fusion.htm) |
| 4.7 | [Form of Ordinary Shares Purchase Warrant issued on July 25, 2025 (incorporated by reference to Exhibit 4.4 to the Form 6-K filed on July 23, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex4-4_fusion.htm) |
| 4.8 | [Form of Securities Purchase Agreement, dated as of July 22, 2025, between Fusion Fuel Green PLC and the other parties signatory thereto (incorporated by reference to Exhibit 10.1 to the Form 6-K filed on July 23, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex10-1_fusion.htm) |
| 4.19 | [Form of Notes Redemption, Warrants Cancellation and Exchange, Limited Waiver, Consent and Release Agreement, dated as of July 22, 2025, between Fusion Fuel Green PLC and the other parties signatory thereto (incorporated by reference to Exhibit 10.2 to the Form 6-K filed on July 23, 2025)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex10-2_fusion.htm) |
| 5.1\* | [Opinion of Arthur Cox LLP](ex5-1.htm) |
| 23.1\* | [Consent of Bush & Associates CPA LLC as to its audit report relating to the financial statements of Fusion Fuel Green PLC](ex23-1.htm) |
| 23.2\* | [Consent of KPMG as to its audit report relating to the financial statements of Fusion Fuel Green PLC](ex23-2.htm) |
| 23.3\* | [Consent of Bush & Associates CPA LLC as to its audit report relating to the financial statements of Quality Industrial Corp.](ex23-3.htm) |
| 23.4\* | [Consent of Arthur Cox LLP (included in Exhibit 5.1)](ex5-1.htm) |
| 24.1\* | [Power of Attorney (included on the signature page of this registration statement)](https://www.sec.gov/Archives/edgar/data/1819794/000121390025066822/ea024997701ex4-4_fusion.htm) |
| 107\* | [Calculation of Filing Fee Table](ex107.htm) |

---

___________________<br> \* Filed herewith.<br>

(b) Financial Statement Schedules.

All financial statement schedules are omitted because the information called for is not required or is shown either in the financial statements or in the notes thereto.

**Item 17. Undertakings**

(a) The
 undersigned registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;(1) To
 file, during any period in which offers or sales are being made, a post-effective amendment
 to this registration statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To
 include any prospectus required by Section 10(a)(3) of the Securities Act of 1933, as amended (the "Securities Act");

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To
 reflect in the prospectus any facts or events arising after the effective date of this registration statement (or the most recent
 post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set
 forth in this registration statement; notwithstanding the foregoing, any increase or decrease in volume of securities offered (if
 the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end
 of the estimated maximum offering range may be reflected in the form of prospectus filed with the Securities and Exchange Commission
 pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
 offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To
 include any material information with respect to the plan of distribution not previously
 disclosed in this registration statement or any material change to such information in this
 registration statement; *provided, however,* that: paragraphs (i), (ii) and (iii) do
 not apply if the registration statement is on Form S-1 and the information required to be
 included in a post-effective amendment by those paragraphs is contained in reports filed
 with or furnished to the Commission by the registrant pursuant to Section 13 or Section 15(d)
 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that
 are incorporated by reference in the registration statement, or is contained in a form of
 prospectus filed pursuant to Rule 424(b) that is part of the registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;(2) That,
 for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a
 new registration statement relating to the securities offered herein, and the offering of such securities at that time shall be deemed
 to be the initial bona fide offering thereof;

&nbsp;&nbsp;&nbsp;&nbsp;(3) To
 remove from registration by means of a post-effective amendment any of the securities being
 registered which remain unsold at the termination of the offering;

(4) To
file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A. of Form 20-F
at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required by
Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of a
post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure that
all other information in the prospectus is at least as current as the date of those financial statements. Notwithstanding the foregoing,
a post-effective amendment need not be filed to include financial statements and information required by Section 10(a)(3) of the Securities
Act or Item 8.A. of Form 20-F if such financial statements and information are contained in periodic reports filed with or furnished
to the SEC by the registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in this registration
statement.

(5) That,
for the purpose of determining liability under the Securities Act to any purchaser

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Each
 prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of the
 date the filed prospectus was deemed part of and included in the registration statement;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Each
 prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration statement in reliance on
 Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii), or (x) for the purpose of providing the information
 required by Section 10(a) of the Securities Act shall be deemed to be part of and included in the registration statement as of the
 earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities
 in the offering described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is
 at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities
 in the registration statement to which that prospectus relates, and the offering of such securities at that time shall be deemed
 to be the initial bona fide offering thereof. Provided, however, that no statement made in a registration statement or prospectus
 that is part of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration
 statement or prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior
 to such effective date, supersede or modify any statement that was made in the registration statement or prospectus that was part
 of the registration statement or made in any such document immediately prior to such effective date; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(5) That,
 for the purpose of determining liability of the registrant under the Securities Act to any purchaser in the initial distribution
 of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant
 to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities
 are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller
 to the purchaser and will be considered to offer or sell such securities to such purchaser:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) Any
 preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule
 424;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) Any
 free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by
 the undersigned registrant;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) The
 portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant
 or its securities provided by or on behalf of the undersigned registrant; and

(iv) Any
 other communication that is an offer in the offering made by the undersigned registrant to the purchaser.

(b) The undersigned registrant
 hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the registrant's annual
 report pursuant to section 13(a) or section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's
 annual report pursuant to section 15(d) of the Exchange Act) that is incorporated by reference in the registration statement shall
 be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
 time shall be deemed to be the initial bona fide offering thereof.

(c) Insofar as indemnification
 for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the registrant
 pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange
 Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the
 event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid
 by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted
 by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in
 the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
 question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication
 of such issue.

(d) The undersigned registrant
 hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) That
 for purposes of determining any liability under the Securities Act, the information omitted
 from the form of prospectus filed as part of this registration statement in reliance upon
 Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule
 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration
 statement as of the time it was declared effective.

(2) For
 the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus
 shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities
 at that time shall be deemed to be the initial bona fide offering thereof.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-3 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dublin, Ireland, on August 8, 2025.

---

| | |
|:---|:---|
| **Fusion Fuel Green PLC** | **Fusion Fuel Green PLC** |
| By: | */s/ John-Paul Backwell* |
|  | John-Paul Backwell<br> Chief Executive Officer |

---

**POWER OF ATTORNEY**

Each person whose signature appears below constitutes and appoints each of John-Paul Backwell and Frederico Figueira de Chaves as his or her true and lawful attorneys-in-fact and agents with full power of substitution and resubstitution, for him or her and his or her name, place and stead, in any and all capacities, to sign any or all amendments (including pre- and post-effective amendments) to this registration statement, any subsequent registration statement for the same offering which may be filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended, and pre- or post-effective amendments thereto, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the foregoing, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ John-Paul Backwell* | Chief Executive Officer (principal executive officer) and Director | August 8, 2025 |
| John-Paul Backwell |  |  |
| */s/ Frederico Figueira de Chaves* | Interim Chief Financial Officer (principal financial officer and principal accounting officer), Chief Strategy Officer, Head of | August 8, 2025 |
| Frederico Figueira de Chaves | Hydrogen Solutions, and Director |  |
| */s/ Jeffrey E. Schwarz* | Chairman of the Board of Directors and Director | August 8, 2025 |
| Jeffrey E. Schwarz |  |  |
| */s/ Rune Magnus Lundetrae* | Director | August 8, 2025 |
| Rune Magnus Lundetrae |  |  |

---

---

| | | |
|:---|:---|:---|
| */s/ Luisa Ingargiola* | Director | August 8, 2025 |
| Luisa Ingargiola |  |  |

---

**SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED STATES**

Pursuant to the Securities Act of 1933, the undersigned, the duly authorized representative in the United States of Fusion Fuel Green PLC has signed this registration statement or amendment thereto on August 8, 2025.

---

| | |
|:---|:---|
| By: | */s/ Jeffrey E. Schwarz* |
| Name: | Jeffrey E. Schwarz |
| Title: | Authorized Representative |

---

## Exhibit 5.1

**Exhibit 5.1**

**Our Reference**: FU049/003

8 August 2025

**PRIVATE AND CONFIDENTIAL**

---

| | |
|:---|:---|
| To: | Board of Directors |
|  | Fusion Fuel Green PLC |
|  | 9 Pembroke Street Upper |
|  | Dublin D02 KR83 |
|  | Ireland |

---

---

| | |
|:---|:---|
| **Re:** | **Fusion Fuel Green plc (the "Company")** |

---

To whom it may concern,

1. **Basis of Opinion (the "Opinion")** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1 We
 act as solicitors in Ireland for the Company, a public limited company organised under the
 laws of Ireland with registration number 669283.

1.2 We
 have been requested to furnish this Opinion in connection with the registration statement
 on Form F-3 filed with the United States Securities and Exchange Commission (the "**SEC** ")
 under the Securities Act of 1933, as amended (the "**Securities Act**") which
 the Company will file on or about the date hereof (the "**Registration Statement** ")
 relating to the registration of up to 3,244,660 Class A Ordinary Shares with a nominal value
 of US$0.0035 each of the Company (the "**Shares**") to be offered and re-sold
 by the Selling Shareholders (as defined in the Registration Statement), pursuant to a Securities
 Purchase Agreement dated 22 July 2025 between the Company and Selling Shareholders (the "**Securities Purchase Agreement** ").

1.3 The
 Shares offered by the Selling Shareholders under the Registration Statement consist of:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) 269,459
 Shares outstanding and issued on 25 July 2025 (the "**SPA Shares**") to the
 Selling Shareholders pursuant to the Securities Purchase Agreement;

(b) 541,706
 Shares (the "**Pre-Funded Warrant Shares**") issuable upon the exercise of
 pre-funded warrants issued to the Selling Shareholders on 25 July 2025 pursuant to the Securities
 Purchase Agreement, which are exercisable for Shares at an exercise price per share of $0.0035
 per share (the "**Pre-Funded Warrants** "), without giving effect to applicable
 limitations or restrictions on exercise;

![](ex5-1_002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c) 1,622,330
 Shares (the "**Market Price Warrant Shares**") issuable upon the exercise
 of warrants issued to the Selling Shareholders on 25 July 2025 pursuant to the Securities
 Purchase Agreement, which are exercisable at an exercise price per share of $4.926 per share
 (the "**Market Price Warrants** "), without giving effect to applicable limitations
 or restrictions on exercise; and

(d) 811,165
 Shares (the "**200% Price Warrant Shares**") issuable upon the exercise of
 warrants issued to the Selling Shareholders on 25 July 2025 pursuant to the Securities Purchase
 Agreement, which are exercisable at an exercise price per share of $9.852 (the "**200% Price Warrants** "), without giving effect to applicable limitations or restrictions
 on exercise.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.4 Terms
 used but not defined herein have the meaning assigned to them in the Registration Statement.
 The Pre-Funded Warrant Shares, the Market Price Warrant Shares and the 200% Price Warrant
 Shares are referred to herein as the "**Warrant Shares** ". The Pre-Funded
 Warrants, the Market Price Warrants and the 200% Price Warrants are referred to herein as
 the "**Warrants** ".

1.5 This
 Opinion is confined to and given in all respects on the basis of the laws of Ireland (meaning
 Ireland exclusive of Northern Ireland) in force as at the date of this Opinion as currently
 applied by the courts of Ireland. We have made no investigations of, and we express no opinion
 as to the laws of, any other jurisdiction or their effect on this Opinion. This Opinion speaks
 only as of its date. We assume no obligation to update this Opinion at any time in the future
 or to advise you of any change in law, change in interpretation of law or change in the practice
 of the Irish Revenue Commissioners which may occur after the date of this Opinion.

1.6 This
 Opinion is also strictly confined to:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the
 matters expressly stated herein at paragraph 2 below and is not to be read as extending by
 implication or otherwise to any other matter;

(b) the
 documents listed in the Schedule to this Opinion (the "**Documents** "); and

(c) the
 searches listed at 1.8 below.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.7 For
 the purpose of giving this Opinion, we have examined copies of the Documents sent to us by
 email by the Company in .pdf or other electronic format.

1.8 For
 the purpose of giving this Opinion, we have caused to be made the following legal searches
 against the Company on 8 August 2025 (the "**Searches** "):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) on
 the file of the Company maintained by the Registrar of Companies in the CRO for mortgages,
 debentures or similar charges or notices thereof and for the appointment of any receiver,
 examiner, process advisor or liquidator;

(b) in
 the Judgments Office of the High Court for unsatisfied judgments, orders, decrees and the
 like for the twelve years immediately preceding the date of the search;

(c) in
 the Central Office of the High Court for any proceedings filed in respect of the Company
 in the five years immediately preceding the date of the search;

![](ex5-1_002.jpg)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d) in
 the Central Office of the High Court for any petitions filed in respect of the Company

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.9 This
 Opinion is governed by and is to be construed in accordance with the laws of Ireland as interpreted
 by the courts of Ireland at the date of this Opinion.

1.10 No
 opinion is expressed as to the taxation consequences of any of the matters referred to in
 the Registration Statement or the transactions referred to therein or contemplated thereby

2. **Opinion** 

Subject to the assumptions set out in this Opinion and to any matters not disclosed to us, we are of the opinion that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1 The
 Company is a public limited company, is duly incorporated and validly existing under the
 laws of Ireland and has the requisite corporate authority to issue the Shares.

2.2 The
 SPA Shares are duly authorized by all necessary corporate action of the Company and are validly
 issued, fully paid and non-assessable (which term means that no further sums are required
 to be paid by the holders thereof in connection with the issue of the SPA Shares).

2.3 The
 Warrant Shares, when issued by the Company in accordance with the terms of the Securities
 Purchase Agreement and the Warrants, will have been duly authorised pursuant to resolutions
 of the board of directors of the Company.

2.4 The
 Warrant Shares, when issued by the Company and, if required, paid for, pursuant to and in
 accordance with the terms and conditions of the Securities Purchase Agreement and the Warrants,
 will be validly issued, fully paid or credited as fully paid and non-assessable (which term
 means that no further sums are required to be paid by the holders thereof in connection with
 the issue of the Shares).

3. **Assumptions** 

For the purpose of giving this Opinion we assume the following, without any responsibility on our part if any assumption proves to have been untrue as we have not verified independently any assumption:

*Registration Statement and the Securities*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.1 That
 the Registration Statement will have become effective under the Securities Act and that the
 Company complies with the statements set out therein.

3.2 That
 the Shares have been issued or will be issued, as applicable (each such issuance, the "**Shares Issuance Event** "), in accordance with the appropriate resolutions and authorities
 of the shareholders and directors of the Company that were passed or are to be passed prior
 to the issue of the Shares and in accordance with the terms of the Registration Statement.

3.3 There
 has been and shall be no fraud on the part of the Company and its respective officers, employees,
 agents and advisers and that the Company has effected or will effect the Shares Issuance
 Event in good faith, for its legitimate and bona fide business purposes.

3.4 That
 (i) the Shares have been or will be listed on The Nasdaq Capital Market tier of The Nasdaq
 Stock Market LLC at the time of their issue or (ii) the Shares will not derive their value
 or the greater part of their value directly or indirectly from land in Ireland, minerals
 in Ireland or any rights, interests or other assets in relation to mining or minerals or
 the searching for minerals or exploration or exploitation rights on the Irish continental
 shelf.

![](ex5-1_002.jpg)

*Authenticity and bona fides*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.5 The
 completeness and authenticity of all Documents submitted to us as originals or copies of
 originals (and in the case of copies, conformity to the originals of such copies), the genuineness
 of all signatories, stamps and seals thereon and where incomplete or draft Documents have
 been submitted to us that the original executed versions of such Documents are identical
 to the last draft of the Documents submitted to us.

3.6 That
 the copies produced to us of minutes of meetings and/or resolutions are true and correct
 copies of the original documents, and the signatures on such documents are genuine.

3.7 That
 the persons identified as the directors of the Company are actually serving as such and that
 any certificates representing the Shares will be properly executed by one or more such persons.

3.8 That
 the Constitution of the Company effective as of 11 July 2025 is the current Constitution,
 is up to date and has not been amended or superseded and that there are no other terms governing
 the Shares other than those set out in the Constitution.

*Accuracy of Searches and the Corporate Certificate*

 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.9 The
 accuracy and completeness of the information disclosed in the Searches and that such information
 is accurate as of the date of this Opinion and has not since the time of such search been
 altered. In this regard, it should be noted that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) the
 matters disclosed in the Searches may not present a complete summary of the actual position
 on the matters we have caused searches to be conducted for;

(b) the
 position reflected by the Searches may not be fully up-to-date; and

(c) searches
 at the CRO do not necessarily reveal whether or not a prior charge has been created or a
 resolution has been passed or a petition presented or any other action taken for the winding-up
 of, or the appointment of a receiver or an examiner or a process advisor to, the Company
 or its assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3.10 The
 truth, completeness and accuracy of all representations and statements as to factual matters
 contained in the Documents.

4. **Disclosure** 

This Opinion is addressed to you in connection with the registration of the Shares with the SEC. We hereby consent to the inclusion of this Opinion as an exhibit to the Registration Statement to be filed with the SEC and to the use of our name in the prospectus that forms part of the Registration Statement.

Yours faithfully,

<u>/s/ Arthur Cox LLP</u>

**ARTHUR COX LLP**

![](ex5-1_002.jpg)

**Schedule 1**

**documents**

---

| | |
|:---|:---|
| 1. | Corporate Certificate dated 8 August 2025, executed by a director of the Company; |
| 2. | Written Resolutions of the Board of Directors of the Company dated 23 July 2025; |
| 3. | Securities Purchase Agreement dated 22 July 2025 between the Company and the Selling Shareholders; |
| 4. | A draft of the Registration Statement sent to us by Bevilacqua PLLC by email on 1 August 2025; |
| 5. | The constitution of the Company. |
|  | (together, the "**Documents**"). |

---

## Exhibit 23.1

**Exhibit 23.1**

![](ex23-1_001.jpg)

To Whom It May Concern:

We consent to the use of our report dated May 9, 2025, relating to the financial statements of Fusion Fuel Green PLC as of and for the year ended December 31, 2024, incorporated herein by reference and to the reference to our firm under the heading "Experts" in the prospectus.

Very truly yours,

/s/ Bush & Associates CPA LLC

Bush & Associates CPA LLC (PCAOB 6797)

Henderson, Nevada

August 8, 2025

## Exhibit 23.2

**Exhibit 23.2**

**Consent of Independent Registered Public Accounting Firm**

We consent to the use of our report dated April 30, 2024, with respect to the consolidated financial statements of Fusion Fuel Green plc, incorporated herein by reference and to the reference to our firm under the heading "Experts" in the prospectus.

/s/ KPMG

Dublin, Ireland

August 8, 2025

## Exhibit 23.3

**Exhibit 23.3**

![](ex23-3_001.jpg)

To Whom It May Concern:

We consent to the use of our report dated March 10, 2025, relating to the financial statements of Quality Industrial Corp. as of and for the years ended December 31, 2023 and 2022, incorporated herein by reference and to the reference to our firm under the heading "Experts" in the prospectus.

Very truly yours,

/s/ Bush & Associates CPA LLC

Bush & Associates CPA LLC (PCAOB 6797)

Henderson, Nevada

August 8, 2025

## Ex-Filing

?xml version='1.0' encoding='ASCII'?

**Exhibit 107**

**Calculation of Filing Fee Table**

Form F-3

(Form Type)

Fusion Fuel Green PLC

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered and Carry Forward Securities

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security Class Title** | **Fee Calculation or Carry Forward Rule** | **Amount Registered**<sup>(1)</sup>** | **Proposed Maximum Offering Price Per Share** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities | Newly Registered Securities |
| Fees to be Paid | Equity | Class A Ordinary Shares with a nominal value of $0.0035 each | Other | 269459 | $5.025 <sup>(2)</sup> | $1354031.48 | 0.00015310 | $207.30 |
| Fees to be Paid | Equity | Class A Ordinary Shares with a nominal value of $0.0035 each underlying Pre-Funded Ordinary Shares Purchase Warrants<sup>(3)</sup> | Other | 541706 <sup>(3)</sup> | $5.025 <sup>(4)</sup> | $2722072.65 | 0.00015310 | $416.75 |
| Fees to be Paid | Equity | Class A Ordinary Shares with a nominal value of $0.0035 each underlying Ordinary Share Purchase Warrants<sup>(5)</sup> | Other | 1622330 <sup>(5)</sup> | $5.025 <sup>(6)</sup> | $8152208.25 | 0.00015310 | $1248.10 |
| Fees to be Paid | Equity | Class A Ordinary Shares with a nominal value of $0.0035 each underlying Ordinary Share Purchase Warrants<sup>(7)</sup> | Other | 811165 <sup>(7)</sup> | $9.852 <sup>(8)</sup> | $7991597.58 | 0.00015310 | $1223.52 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $20219909.96 |  | $3095.67 |
|  | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** | **Total Fees Previously Paid** |  |  |  | $0.00 |
|  | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** | **Total Fee Offsets** |  |  |  | $0.00 |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $3095.67 |

---

(1) Pursuant
 to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"),
 there is also being registered hereby such indeterminate number of additional Class A ordinary
 shares with a nominal value of $0.0001 each ("Class A Ordinary Shares"), as may
 be issued or issuable because of share splits, share dividends and similar transactions.

(2) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under
 the Securities Act, based upon the average of the high and low prices of the Class A Ordinary
 Shares reported by The Nasdaq Stock Market LLC ("Nasdaq") on August 5, 2025.

(3) Consists
 of an aggregate of 541,706 Class A Ordinary Shares issuable upon exercise of certain Pre-Funded
 Ordinary Shares Purchase Warrants issued on July 25, 2025 with an initial exercise price
 of $0.0035 per share.

(4) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under
 the Securities Act, based upon the average of the high and low prices of the Class A Ordinary
 Shares reported by Nasdaq on August 5, 2025.

(5) Consists
 of an aggregate of 1,622,330 Class A Ordinary Shares issuable upon exercise of certain Ordinary
 Share Purchase Warrants issued on July 25, 2025 with an initial exercise price of $4.926
 per share.

(6) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under
 the Securities Act, based upon the average of the high and low prices of the Class A Ordinary
 Shares reported by Nasdaq on August 5, 2025.

(7) Consists
 of an aggregate of 811,165 Class A Ordinary Shares issuable upon exercise of certain Ordinary
 Share Purchase Warrants issued on July 25, 2025 with an initial exercise price of $9.852
 per share.

(8) Estimated
 solely for the purpose of calculating the registration fee pursuant to Rule 457(g) under
 the Securities Act, based on the exercise price of the warrants.